Evidence map›Paper›PMID 29399522›Full record

ReviewCardiovascular diagnosis and therapy2017

Can thrombus age guide thrombolytic therapy?

Christopher Czaplicki, Hassan Albadawi, Sasan Partovi, Ripal T Gandhi, Keith Quencer, Amy R Deipolyi, Rahmi Oklu

Open access · bronzeAbstract readReview
In one paragraph

Review in Cardiovascular diagnosis and therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed
3.9field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 90 citations in OpenAlex.

  1. Molecular-gated MRIMaterials today. Bio · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Overview of Therapeutic Ultrasound Applications and Safety Considerations: 2024 Update.Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine · 2025
    Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Aging of deep venous thrombosisBiomedical optics express · 2024
    Article
  15. Article
  16. Article
  17. Review
  18. Mechanical Thrombectomy for High-Risk Pulmonary Embolism: Insights From the US Cohort of the FLASH Registry.Journal of the Society for Cardiovascular Angiography & Interventions · 2024
    Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 1 country.

Christopher CzaplickiDivision of Vascular & Interventional Radiology, Mayo Clinic, Phoenix, AZ, USA.
Hassan AlbadawiDivision of Vascular & Interventional Radiology, Mayo Clinic, Phoenix, AZ, USA.
Sasan PartoviUniversity Hospitals Case Medical Center, Case Western Reserve University, Cleveland, OH, USA.
Ripal T GandhiMiami Cardiac and Vascular Institute, University of South Florida College of Medicine, Kendall, FL, USA.
Keith QuencerDepartment of Radiology, University of California San Diego Medical Center, San Diego, CA, USA.
Amy R DeipolyiDepartment of Interventional Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Rahmi OkluDivision of Vascular & Interventional Radiology, Mayo Clinic, Phoenix, AZ, USA.
Mayo Clinic in Florida · USMemorial Sloan Kettering Cancer Center · USUniversity Hospitals Case Medical Center · USUniversity of California San Diego Medical Center · USUniversity of South Florida · US

Funding

Hemorrhage control in the irreversible anticoagulated patientR01HL137193 · NHLBI · MAYO CLINIC ARIZONA · PI OKLU, RAHMI · 2017 to 2021
$3.0M
Targeted chemotherapy delivery and captureR01EB024403 · NIBIB · MAYO CLINIC ARIZONA · PI KHADEMHOSSEINI, ALI, OKLU, RAHMI · 2017 to 2020
$2.2M
Catheter guided endovascular electric field ablation for thrombosis therapy.R21EB021148 · NIBIB · MAYO CLINIC ARIZONA · PI KHADEMHOSSEINI, ALI, OKLU, RAHMI · 2016 to 2017
$485k
Circulating tumor cells in hepatocellular carcinomaR03CA172738 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI TONER, MEHMET · 2013 to 2014
$171k
NCI NIH HHS R03 CA172738NHLBI NIH HHS R01 HL137193NIBIB NIH HHS R01 EB024403NIBIB NIH HHS R21 EB021148
6 · The paper itself

Abstract

Venous thrombosis (VT) is a common yet complex clinical condition that has shown minimal alteration in clinical management for decades. It is well known that thrombus evolves structurally over time, with complex changes resulting from the interplay between coagulation factors, cytokines, leukocytes and a myriad of other factors. Our current treatment options are most effective in the acute thrombus, which is composed predominantly of a loose mesh of fibrin and red blood cells (RBCs), making current anticoagulation therapies and thrombolytics quite effective in treatment. Later stages of thrombus are more cellular containing leukocytes, and develop a fibrotic collagenous framework that is more resistant to our current treatments. Understanding the biology of an evolving thrombus will allow us to tailor our treatment and optimize outcomes, as well as focus on novel therapies for the treatment of chronic thrombus. Given the morbidity and mortality of both post thrombotic syndrome (PTS) in patients with deep VT, as well as chronic thromboembolic pulmonary hypertension (CTEPH) in patients with pulmonary embolism (PE), new and innovative therapies must continue to be explored to help prevent these potentially devastating conditions.

Indexed as

Anticoagulantspulmonary embolism (PE)venous thromboembolismvenous thrombosis (VT)

Identifiers

PMID29399522
PMCPMC5778517
OpenAlexW2773826605

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.